Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04840719
Other study ID # KY 2019-080-03
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date May 22, 2020
Est. completion date July 30, 2022

Study information

Verified date April 2021
Source Beijing Tiantan Hospital
Contact Baixue Jia, PhD,MD
Phone 86-010-67098857
Email beckyberry@163.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Investigate Reco ® ,the first clot retriever in china as the primary therapyand remedies in the real world.


Description:

Endovascular thrombectomy (EVT) is effective and safe for acute ischemic stroke (AIS) caused by large vessel occlusion (LVO) in major clinical trials. Whether the benefit of EVT in randomized trials could be generalized to clinical practice, especially in developing countries, remains unknown. The Registry was established to evaluate the utilization, and subsequent outcomes of EVT treated AIS patients. This study is a multi-center, prospective registry study initiated by researchers, to investigate Reco ® ,the first clot retriever in china as the primary therapyand remedies in the real world.


Recruitment information / eligibility

Status Recruiting
Enrollment 1000
Est. completion date July 30, 2022
Est. primary completion date December 31, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Age = 18 years old 2. Diagnosis of acute ischemic stroke 3. Imaging confirmed intracranial large artery occlusion (LVO): intracranial internal carotid artery (ICA T/L), middle cerebral artery (MCA M1/M2), anterior cerebral artery (ACA A1/A2), basilar artery (BA), vertebral artery (VA V4), and posterior cerebral artery (PCA P1);ASPECT or PC-ASPECT = 6 4. Initiation of any type of endovascular treatment (EVT), including intra-arterial thrombolysis, mechanical thrombectomy, angioplasty, and stenting 5. The patient or the patient's legal representative is able and willing to sign the informed consent Exclusion Criteria: 1. Isolated cervical ICA or VA occlusion; 2. No evidence of LVO on DSA.

Study Design


Related Conditions & MeSH terms

  • Infarction
  • Intracranial Artery Occlusion With Infarction (Disorder)

Intervention

Device:
RECO


Locations

Country Name City State
China Beijing Tiantan Hospital Beijing Beijing

Sponsors (1)

Lead Sponsor Collaborator
Beijing Tiantan Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Functional independence at 90 days (modified Rankin Scale of 0-2) The range of modified Rankin Scale was from 0 to 6. 0-No symptoms;1-No significant disability;2-Slight disability;3-Moderate disability;4-Moderately severe disability;5-Severe disability;6 -Dead.A higher score indicates worse a outcome. [90±7 days after procedure]
Primary Symptomatic intracranial hemorrhage (sICH) within 12-36 hours after the procedure Heidelberg Bleeding Classification): new intracranial hemorrhage detected by brain imaging associated with =4 points total National Institutes of Health Stroke Scale (NIHSS), =2 points in one NIHSS category, leading to intubation/ hemicraniectomy/ EVD placement or other major medical/surgical intervention, or absence of alternative explanation for deterioration 12-36 hours after the procedure
Primary Time from symptom onset to recanalization Minutes From the time of symptom onset until the time of of the recanalization of the occluded artery, assessed up to 48 hours
Secondary Recanalization rate at the end of the procedure modified thrombolysis in cerebral infarction (mTICI) 2b-3 Immediately after the procedure
Secondary Recanalization rate after the first attempt mTICI score 2b-3 Immediately after the first attempt of endovascular treatment
Secondary Changes in NIHSS score immediately after the procedure difference between NIHSS score immediately after the procedure and baseline within 2 hours after the procedure
Secondary Changes in NIHSS score 24 hours after the procedure difference between NIHSS score 24 hours after the procedure and baseline 24 hours after the procedure
Secondary Changes in NIHSS score 7 days after the procedure or at discharge difference between NIHSS score 7 days after the procedure or discharge and baseline 7 days after the procedure or discharge
Secondary EQ-5D 90 days after the procedure EQ-5D is a standardized instrument for measuring generic health status. Rated level can be coded as a number 1, 2, or 3, which indicates having no problems for 1, having some problems for 2, and having extreme problems for 3. As a result, a person's health status can be defined by a 5-digit number, ranging from 11111 (having no problems in all dimensions) to 33333 (having extreme problems in all dimensions).A higher score indicates a better outcome. 90±7 days after the procedure
Secondary Barthel index (BI) 90 days after the procedure The BI has a score of 0-100. A higher score indicates a better outcome. 90±7 days after the procedure
Secondary Parenchymal hematoma (PH2) PH2 is defined as the rate of hematoma >30percent in infarct area 12-36 hours after the procedure
Secondary Any intracranial hemorrhage on imaging Based on the image 12-36 hours after the procedure
Secondary All-cause mortality within 90 days mortality 90±7 days after the procedure
Secondary Time from onset to arrival record the time At baseline, after arrival at the hospital immediately
Secondary Time from arrival to imaging record the time At baseline, after taking any brain imaging immediately
Secondary Time from imaging to puncture record the time At baseline, during the procedure, after successful groin puncture immediately
Secondary Time from puncture to recanalization record the time At baseline, during the procedure, after successful recanalization immediately
See also
  Status Clinical Trial Phase
Completed NCT03370939 - Endovascular Treatment Key Technique and Emergency Work Flow Improvement of Acute Ischemic Stroke
Recruiting NCT04151589 - Endovascular Treatment Key Technique and Emergency Work Flow Improvement of Acute Ischemic Stroke (ANGEL-ACT): Phase Two N/A